Publications by authors named "B Massida"
Article Synopsis
- This study examines the efficacy and safety of 3 months versus 6 months of oxaliplatin-based adjuvant chemotherapy in patients with radically resected stage II/III colon cancer, aiming to determine if a shorter treatment duration is just as effective.
- Results showed that patients receiving 3 months of chemotherapy had better treatment compliance and experienced significantly fewer severe toxicities compared to those on 6 months of treatment, particularly in terms of neuropathy and treatment discontinuation rates.
- The TOSCA trial's findings suggest that shorter adjuvant chemotherapy may be a viable option, potentially benefiting patients by reducing the burden of treatment while maintaining effectiveness.
